New radioactive drug tested for Hard-to-Treat tumors
Disease control
Ongoing
This early-stage study tests a new radioactive drug called [212Pb] VMT-alpha-NET in 24 adults with advanced neuroendocrine tumors that have stopped responding to other treatments. The main goal is to find a safe dose for future studies, not to provide direct benefit. Participants…
Phase: EARLY_PHASE1 • Sponsor: David Bushnell • Aim: Disease control
Last updated May 11, 2026 20:38 UTC